Add to ORKGCancers other than breast, colorectal, cervical, and lung do not have guideline-recommended screening. New multi-cancer early detection (MCED) tests—using a single blood sample—have been developed based on circulating cell-free DNA (cfDNA) or other analytes. In this commentary, we review the current evidence on these tests, provide several major considerations for new MCED tests, and outline how their evaluation will need to differ from that established for traditional single-cancer screening tests
In the Circulating Cell-free Genome Atlas (NCT02889978) substudy 1, we evaluate several approaches f...
Abstract Diagnosis of cancer at an early stage leads to improved survival. However, most current blo...
Abstract Various recent studies have focused on analyzing tumor genetic material relea...
Multicancer Early Detection (MCED) represents a new and exciting paradigm for the early detection of...
Cancer detection tests open a new era of developing cancer markers, allowing early detection and imp...
BACKGROUND: A multi-cancer early detection (MCED) test used to complement existing screening could i...
Identifying circulating cell-free tumour DNA in blood offers the potential for multi-cancer early de...
We recently published some concerns with new technologies which are based on circulating tumor DNA (...
BACKGROUND: A multi-cancer early detection (MCED) test used to complement existing screening could i...
While testing for easily accessible biomarkers in the circulation (“liquid biopsy”) has found its wa...
While testing for easily accessible biomarkers in the circulation (“liquid biopsy”) has found its wa...
Background: Multi-cancer early detection (MCED) next-generation-sequencing blood tests represent a ...
Early detection of cancer saves lives, but an effective detection strategy in public health settings...
In the Circulating Cell-free Genome Atlas (NCT02889978) substudy 1, we evaluate several approaches f...
In the Circulating Cell-free Genome Atlas (NCT02889978) substudy 1, we evaluate several approaches f...
In the Circulating Cell-free Genome Atlas (NCT02889978) substudy 1, we evaluate several approaches f...
Abstract Diagnosis of cancer at an early stage leads to improved survival. However, most current blo...
Abstract Various recent studies have focused on analyzing tumor genetic material relea...
Multicancer Early Detection (MCED) represents a new and exciting paradigm for the early detection of...
Cancer detection tests open a new era of developing cancer markers, allowing early detection and imp...
BACKGROUND: A multi-cancer early detection (MCED) test used to complement existing screening could i...
Identifying circulating cell-free tumour DNA in blood offers the potential for multi-cancer early de...
We recently published some concerns with new technologies which are based on circulating tumor DNA (...
BACKGROUND: A multi-cancer early detection (MCED) test used to complement existing screening could i...
While testing for easily accessible biomarkers in the circulation (“liquid biopsy”) has found its wa...
While testing for easily accessible biomarkers in the circulation (“liquid biopsy”) has found its wa...
Background: Multi-cancer early detection (MCED) next-generation-sequencing blood tests represent a ...
Early detection of cancer saves lives, but an effective detection strategy in public health settings...
In the Circulating Cell-free Genome Atlas (NCT02889978) substudy 1, we evaluate several approaches f...
In the Circulating Cell-free Genome Atlas (NCT02889978) substudy 1, we evaluate several approaches f...
In the Circulating Cell-free Genome Atlas (NCT02889978) substudy 1, we evaluate several approaches f...
Abstract Diagnosis of cancer at an early stage leads to improved survival. However, most current blo...
Abstract Various recent studies have focused on analyzing tumor genetic material relea...